A practical reference on SR9009: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-15. Anything still debated is marked as such rather than presented as settled.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
== Synthesis == Phosphorimidazolide reagents have been synthesized from phosphate mono-esters. In one method, a phosphate mono-ester is dissolved in anhydrous pyridine or N,N-dimethylformamide (DMF) and activated using triphenylphosphine (PPh3) and 2,2’-Dithiodipyridine (2,2’-DTDP) in the presence of triethylamine (TEA) base and excess imidazole. In another method using fewer reagents, a phosphate mono-ester is dissolved in DMF and carbonyldiimidazole (CDI) is used to both remove an oxygen atom from the phosphate group and supply the imidazole substituent. The product of either reaction may be collected by precipitation using acetonitrile or acetone as antisolvent with sodium or lithium perchlorate to supply the sodium or lithium salt of the phosphorimidazolide respectively. Alternatively, the phosphorimidazolide may be isolated by reverse-phase flash column chromatography with TEAB buffer and acetonitrile.
The epithelial lining of the mucosa, differs along the gastrointestinal tract. The epithelium is described as stratified if it consists of multiple layers of cells, and simple if it is made up of one layer of cells. Terms used to describe the shape of the cells in it - columnar if column-shaped, and squamous if flat.
Psilocybe semilanceata fruits solitarily or in groups on rich and acidic soil, typically in grasslands, such as meadows, pastures, or lawns. It is often found in pastures that have been fertilized with sheep or cow dung, although it does not typically grow directly on the dung. P. semilanceata, like all others species of the genus Psilocybe, is a saprobic fungus, meaning it obtains nutrients by breaking down organic matter. The mushroom is also associated with sedges in moist areas of fields, and it is thought to live on the decaying root remains. At least one study has demonstrated an association of P. semilanceata with the roots of the grasses Agrosiis tenuis, Poa annua, and the dicot Lolium perenne. Like some other grassland psilocybin mushroom species such as P. mexicana, P. tampanensis and Conocybe cyanopus, P. semilanceata may form sclerotia, a dormant form of the fungus, which affords it some protection from wildfires and other natural disasters. Laboratory tests have shown P. semilanceata to suppress the growth of the soil-borne water mold Phytophthora cinnamomi, a virulent plant pathogen that causes the disease root rot. When grown in dual culture with other saprobic fungi isolated from the rhizosphere of grasses from its habitat, P. semilanceata significantly suppresses their growth. This antifungal activity, which can be traced at least partly to two phenolic compounds it secretes, helps it compete successfully with other fungal species in the intense competition for nutrients provided by decaying plant matter.
Future space exploration and terraforming efforts may depend on in situ resource utilization, reducing reliance on Earth-based supplies. Proposed missions, such as Orion and Mars Direct, have explored this approach by leveraging locally available materials. The Orion space vehicle was once considered for propulsion using fuel extracted from the Moon, while Mars Direct relies on the Sabatier reaction to synthesize methane and water from atmospheric carbon dioxide and hydrogen on Mars.
== Detection and classification == Detection of drugs and pharmaceuticals in biological samples is usually done by an initial screening and then a confirmation of the compound(s), which may include a quantitation of the compound(s). The screening and confirmation are usually, but not necessarily, done with different analytical methods. Every analytical method used in forensic toxicology should be carefully tested by performing a validation of the method to ensure correct and indisputable results at all times. The choice of method for testing is highly dependent on what kind of substance one expects to find and the material on which the testing is performed. Customarily, a classification scheme is utilized that places poisons in categories such as: corrosive agents, gases and volatile agents, metallic poisons, non-volatile organic agents, and miscellaneous.
Sources: en.wikipedia.org
The Tanukhids were Christianised in the 3rd or 4th centuries, likely while in the eastern half of the Fertile Crescent, and by the 4th century they were described as having a "fanatic zeal for Christianity" and were "zealous Christian soldiers" in the 6th century. In the 7th century, during the Muslim conquest of the Levant, the Tanukhids fought with the Romans against the Muslims, including in the Battle of Yarmouk. After Yarmouk, their status as foederati ended. They were described as an "autonomous Christian community in Bilad al-Sham" up until the reign of the Abbasid caliph al-Mahdi (r. 775–785), after which they appear as Muslims. Their conversion to Islam is believed to have been forced upon them by al-Mahdi. They are reported to have been devoted to Christianity, Thomas the Apostle and monasticism, with many monasteries associated with the tribe. Epistle 50, one of the Epistles of Wisdom composed by Druze missionaries in the early 11th century, was explicitly directed to three Tanukhid emirs settled in the mountainous Gharb area southeast of Beirut, calling on them to continue the tradition of their ancestors in spreading Druze teachings. The Gharb was less rugged than the neighboring areas to the north and south, and its strategic value stemmed from its control of Beirut's southern harbor and the road connecting Beirut with Damascus. The warrior peasants who inhabited the Gharb subscribed to the Druze faith, an esoteric offshoot of Isma'ili Shia Islam, the religion of the Fatimid caliphs of Egypt.
The foundations for Jung's typology of psychological types were in his early research at the Burghölzli Hospital. Through the Word Association Experiment, Jung provided the first empirical evidence of "complexes", observing that individuals showed distinct patterns in how they responded to emotional disturbances: some subjects were consistently oriented toward the objective meaning of the stimulus (extraverted tendency), while others were derailed by internal, subjective associations (introverted tendency). Jung interpreted what he saw as a fundamental divergence in how psychic energy (libido) moved in psychiatric patients. He noted that in hysteria, energy flowed outward toward the object, whereas in dementia praecox (schizophrenia), energy withdrew into a subjective inner world. By 1913, Jung concluded that these were not merely symptoms of illness but exaggerated manifestations of normal psychological orientations. The further differentiation of the four psychological functions (thinking, feeling, sensation, and intuition) emerged from Jung's period of intense self-experimentation between 1913 and 1917. Documented in The Red Book (Liber Novus), Jung utilised the method of active imagination to observe his own mental processes. This introspection allowed him to map how certain functions dominate consciousness while their opposites remain "inferior" and unconscious. By comparing these personal findings with the case histories of his patients, Jung moved from a simple two-fold model (extraversion/introversion) to the complex eight-fold functional system published in 1921.
MyFerryLink LD Lines SeaFrance Norfolkline Stena Line P&O Stena Line Townsend Thoresen Normandy Ferries Sealink (later Sealink Stena Line) and four companies under the tag: Regie voor Maritiem Transport Stoomvaart Maatschappij Zeeland SNCF British Rail An adjacent freight terminal (with three loading cranes) is scheduled to be repurposed under port redevelopment plans but can currently be used by ships of up to 180 metres (590 ft).
==== Quantum hall effect in graphene ==== The quantum Hall effect is a quantum mechanical version of the Hall effect, which is the production of transverse (perpendicular to the main current) conductivity in the presence of a magnetic field. The quantization of the Hall effect
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.